News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,777 Results
Type
Article (39733)
Company Profile (247)
Press Release (659797)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204188)
Career Advice (2008)
Deals (35422)
Drug Delivery (96)
Drug Development (81053)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345226)
Policy (32543)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49444)
ALS (93)
Alzheimer's disease (1382)
Antibody-drug conjugate (ADC) (132)
Approvals (16186)
Artificial intelligence (261)
Autoimmune disease (22)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (290)
Cancer (2306)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (154)
Cell therapy (433)
Cervical cancer (20)
Clinical research (66066)
Collaboration (853)
Company closure (2)
Compensation (557)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (249)
Cystic fibrosis (101)
Data (2297)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6378)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (102)
Drug shortages (25)
Duchenne muscular dystrophy (96)
Earnings (86981)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112612)
Executive appointments (737)
FDA (17552)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (764)
Gene editing (109)
Generative AI (19)
Gene therapy (308)
GLP-1 (716)
Government (4427)
Grass and pollen (4)
Guidances (150)
Healthcare (18818)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (121)
Indications (29)
Infectious disease (2734)
Inflammatory bowel disease (143)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (97)
Interviews (312)
IPO (16524)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (324)
Lymphoma (156)
Machine learning (9)
Management (58)
Manufacturing (323)
MASH (73)
Medical device (13383)
Medtech (13388)
Mergers & acquisitions (19466)
Metabolic disorders (702)
Multiple sclerosis (82)
NASH (16)
Neurodegenerative disease (91)
Neuropsychiatric disorders (27)
Neuroscience (1929)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (204)
Ovarian cancer (80)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (150)
Partnered (21)
Patents (241)
Patient recruitment (115)
Peanut (46)
People (57340)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase I (20580)
Phase II (29102)
Phase III (21668)
Pipeline (1344)
Policy (146)
Postmarket research (2563)
Preclinical (8756)
Press Release (64)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (382)
Real estate (5907)
Recruiting (65)
Regulatory (22321)
Reports (47)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (70)
Series A (131)
Series B (87)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3579)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (48)
The Weekly (30)
Vaccines (697)
Venture capitalists (42)
Weight loss (236)
Women's health (36)
Worklife (16)
Date
Last 7 days (927)
Last 30 days (2984)
Last 365 days (32336)
2025 (11662)
2024 (35219)
2023 (40079)
2022 (51174)
2021 (55711)
2020 (54083)
2019 (46539)
2018 (35018)
2017 (32110)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28571)
2011 (29263)
2010 (27329)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37872)
Australia (6190)
California (6366)
Canada (2059)
China (532)
Colorado (271)
Connecticut (278)
Delaware (156)
Europe (81377)
Florida (946)
Georgia (212)
Idaho (57)
Illinois (545)
India (25)
Indiana (318)
Iowa (11)
Japan (171)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (918)
Massachusetts (4727)
Michigan (223)
Minnesota (401)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (63)
New Jersey (1782)
New Mexico (28)
New York (1794)
North Carolina (985)
North Dakota (8)
Northern California (2801)
Ohio (208)
Oklahoma (14)
Oregon (34)
Pennsylvania (1417)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (25)
South Dakota (1)
Southern California (2398)
Tennessee (105)
Texas (944)
United States (23852)
Utah (188)
Virginia (151)
Washington D.C. (64)
Washington State (561)
West Virginia (3)
Wisconsin (56)
699,777 Results for "lyell immunopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Lyell Cuts 73 Employees as Part of LA Site Closure
After moving the manufacturing of a CAR T drug that was part of its ImmPACT Bio acquisition to Washington, Lyell Immunopharma is closing its Los Angeles manufacturing facility, eliminating dozens of jobs there.
April 7, 2025
·
1 min read
·
Angela Gabriel
Press Releases
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
February 19, 2025
·
1 min read
Press Releases
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
March 12, 2025
·
19 min read
Press Releases
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
April 15, 2025
·
8 min read
Press Releases
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
May 1, 2025
·
4 min read
Biotech Bay
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - June 3, 2024
Lyell Immunopharma, Inc today announced that members of its senior management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 pm ET.
June 3, 2024
·
1 min read
Biotech Bay
Lyell Immunopharma to Participate in BofA Securities Health Care Conference 2024
Lyell Immunopharma, Inc. announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT.
May 7, 2024
·
1 min read
Press Releases
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
October 31, 2024
·
6 min read
Business
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the first quarter ended March 31, 2024.
May 6, 2024
·
13 min read
Biotech Bay
Lyell Immunopharma Announces Participation in March 2024 Investor Conferences
Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that members of its senior management team will present and participate the following upcoming investor conferences:
February 26, 2024
·
1 min read
1 of 69,978
Next
